Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX2001 in Advanced or Metastatic Solid Tumors
NCT05407909Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jul 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYHX2001 in solid tumor (advanced stage) and metastatic solid tumors (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose limiting toxicities at Day 28, Maximum tolerated dose at Day 28 and 3 more. Started Jul 2022; status: recruiting.
02
Drugs
SYHX2001
03
Conditions
solid tumor (advanced stage)metastatic solid tumors
Beyond the preview
Go deeper on NCT05407909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407909.